News and Announcements
Proteomics International Laboratories Ltd CEO Interview
- Published February 04, 2015 12:19PM UTC
- Publisher Wholesale Investor
- Categories Executive Interviews
Proteomics International Laboratories Ltd (PILL) is an innovative biological research and drug discovery company specialising in the development of simple diagnostic tests for common diseases and the discovery of new therapeutic drugs to treat pain and infection. The Company, based in Perth, Western Australia, works across three units – diagnostics, therapeutics and analytical services.
The Company now seeks additional funding of $6 million to expand each business unit and accelerate commercialisation. It focuses on utilising the funds raised to commercialise the already-developed IP, and implement a measured programme for further compound discovery, whilst expanding existing revenues to underpin future efforts.
To find out more about PILL please listen to Dr Richard Lipscombe, Managing Director.
Executive Interviews
Following the Billions: Where the Hyperscalers are Betting on the Future
The roadmap for the next decade isn’t hidden in pitch decks—it’s written on the balance sheets of Microsoft, Amazon, and Google. Their collective investment is flowing into three key areas: GPU Chips, AI Factories, and Energy. This foundational buildout signals a $7–$20 trillion economic convergence, where the physical race for infrastructure and energy is paramount. The article also covers the powerful macro case for digital assets in this new era.
The Great Re-Allocation: Why AI is Forcing Smart Money From Software to Hard Science
Smart money is rapidly shifting its investment focus from commoditized software to hard science and deep tech, as AI dissolves traditional software moats. Discover the dual pressure on investors and the pivot to businesses with durable, real-world defensive barriers.
AI is The Cheapest, Highest-Leverage Investment You Will Ever Make
AI tools offer a 10x productivity increase for a minimal monthly cost, making them the highest-ROI investment in business today. However, this massive potential remains dormant. The real opportunity is not in owning the tools, but in having the strategic playbook to deploy them organization-wide and build a defensible competitive advantage.
Backed By Leading Investment Groups and Family Offices
